article thumbnail

Bayer to present latest research across its advancing oncology portfolio at AACR 2023 Annual Meeting

The Pharma Data

Bayer will present the first clinical Phase 1 results on aryl hydrocarbon receptor (AhR) inhibitor BAY 2416964, the company’s most advanced Immuno-Oncology program.